<DOC>
	<DOC>NCT00251004</DOC>
	<brief_summary>The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.</brief_summary>
	<brief_title>Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male and female patients of any race between 18 to 70 years old (inclusive) Patients who gave written informed consent to participate in the study Recipients of multiorgan transplantation Recipients of a primary cadaveric or primary nonhuman leucocyte antigen (HLA) identical living donor kidney transplantation. Graft cold ischemia time greater than 40 hours. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Renal transplantation, kidney, and organ transplant</keyword>
	<keyword>Renal transplant rejection</keyword>
</DOC>